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Updates for the District of Columbia:
● Phase Two of the District’s reopening has begun, as of Monday, June 22. As a necessary precondition,
the District has experienced two weeks of sustained decrease in community spread of COVID-19.
● As of June 21, the District’s overall positive case total was 10,058 with 535 deaths. Death
demographics: 74% African American, 13% Latinx, 11% White, 1% Asian; 58% male, 42% female.
● As of June 21, hospital occupancy is 74 % in DC; the proportion of occupancy due to COVID-19 is low
(155 of 1,848 total) and ventilator utilization remains below 50%.
Preventing transmission of COVID-19:
● As more states and locales are opening, comprehensive guidance is available for employers on how to
prevent transmission of COVID-19 in the workplace. Suggested public health measures include use of
PPE, reducing the density/segmenting the workforce, environmental controls and testing.
● The Centers for Disease Control and Prevention has released guidance for businesses, as well as
considerations and guidance for institutions of higher learning.
Key updates in treatment for COVID-19:
● One RCT study found that among patients with severe or life-threatening COVID-19, convalescent
plasma therapy added to standard treatment did not significantly improve the time to clinical
improvement within 28 days. However, the study authors noted that the trial was terminated early
and may have been underpowered to detect a clinically important difference.
● Hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) are no longer authorized by FDA to
treat COVID-19. Further, FDA is warning health care providers that co-administration of remdesivir and
chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced
antiviral activity of remdesivir.
● Massachusetts General Hospital published a new comprehensive resource for treatment of patients
with COVID-19.
● Researchers are beginning to learn why some patients with COVID-19 fare worse, identifying a genetic
susceptibility locus and involvement of the ABO blood-group system. (Blood group A appears to lead to
higher risk and blood group O may have a protective effect.)
● Emerging evidence:
o Preliminary results for an open label randomized controlled trial (RCT) in the United Kingdom
found that dexamethasone can reduce mortality by one-third for ventilated patients and onefifth for patients requiring only oxygen; there was no mortality benefit in patients on room air.
These findings have not been peer-reviewed and were described pre-print in a press release.
o Two studies have been released that suggest Anakinra may be a potential treatment: In one
small, uncontrolled study using Anakinra 100mg every 8 hours the authors found rapid clinical
improvement and a clinical trial is now underway. A second retrospective cohort study of nonventilated patients with COVID-19 and ARDS found treatment with high-dose Anakinra (5
mg/kg IV BID) was safe and associated with clinical improvement in 72 percent of patients. At
21 days, survival was 90% in the high-dose Anakinra group and 56% in the standard treatment
group.
o One study in 100 patients, Tocilizumab infusion resulted in improved or stabilized clinical
improvement at 10 days in 77 patients, of whom 61 showed a significant clearing of diffuse
bilateral opacities on chest X-ray and 15 were discharged from the hospital. Respiratory
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condition worsened in 23 patients, of whom 20 died.
Care for patients with autoimmune disease and COVID-19:
● The COVID-19 Global Rheumatology Alliance Physician-Reported Registry found that glucocorticoid
exposure of ≥10 mg/day is associated with a higher odds of hospitalization and anti-tumor necrosis
factor with a decreased odds of hospitalization in patients with rheumatic disease. Exposure to nonbiologic disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs were not
associated with increased odds of hospitalization.
● Patients with lupus—even if they are using an antimalarial such as hydroxychloroquine as baseline
therapy—can develop SARS-CoV-2 infection and severe COVID-19 at similar frequency as patients with
lupus not on antimalarials.
● In a cohort of patients with rheumatic and musculoskeletal diseases in a geographical region with a
high prevalence of COVID-19, a poor outcome from COVID-19 seemed to be associated with older age
and the presence of comorbidities rather than the type of rheumatic disease or the degree of
pharmacological immunosuppression.
Policy Updates:
● The Assistant Secretary of Preparedness and Response (ASPR) has released a resource highlighting
interrelated issues for healthcare systems to consider as they resume services, which include restoring
services that have been curbed, maintaining readiness for potential future waves of COVID-19
patients, and adapting to improve their operations based on lessons learned.
● ASPR has published recommendations pertaining to civil unrest during a pandemic to help
stakeholders with planning and response efforts.
● The HHS Office of Civil Rights has clarified that generally, a covered health care provider may use PHI
to identify patients who have recovered from COVID-19 to provide them with information about how
they can donate their blood and plasma containing antibodies to the virus that causes COVID-19, to
help treat other patients with COVID-19.
● Medical educators are grappling with disruptions in residency training during the pandemic. Some
argue for a transition from time-based to competency-based, time-variable graduate medical
education (GME), in which each physician graduates from residency (or fellowship) to unsupervised
practice when — and only when — the necessary competencies are achieved.
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Stay safe and informed.

